Technical Analysis for RVNC - Revance Therapeutics, Inc.

Grade Last Price % Change Price Change
F 11.75 -2.81% -0.34
RVNC closed down 2.81 percent on Thursday, September 28, 2023, on 80 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
NR7 Range Contraction 0.00%
NR7-2 Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Oversold Stochastic Weakness 0.00%
New 52 Week Closing Low Bearish -2.81%
Calm After Storm Range Contraction -2.81%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Possible NR7 about 10 hours ago
Down 3% about 14 hours ago
Down 2 % about 14 hours ago
Fell Below Previous Day's Low about 14 hours ago
Down 1% about 14 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Revance Therapeutics, Inc. Description

Revance Therapeutics, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of novel botulinum toxin products for various aesthetic and therapeutic applications worldwide. Its lead product candidate is RT001, a topical gel formulation of botulinum toxin type A, which is in Phase III clinical trials for the treatment of crow's feet lines; has completed initial Phase II clinical trials for the treatment of hyperhidrosis and for the prevention of migraine headache; and has completed Phase I clinical trials for the treatment of other indications, such as neuropathic pain and rhinitis. The company is also developing RT002, a novel injectable formulation of botulinum toxin type A, which is being tested in the four-cohort Phase I/II clinical dose escalation trials for the treatment of glabellar lines. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was founded in 1999 and is based in Newark, California.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Drugs Pain Toxins Neuropathic Pain Plastic Surgery Migraine Headache Botulinum Toxin Botulism Migraine Headache Therapeutic Applications Neurotoxins Rhinitis

Is RVNC a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 37.98
52 Week Low 11.1
Average Volume 1,887,648
200-Day Moving Average 26.72
50-Day Moving Average 18.32
20-Day Moving Average 15.13
10-Day Moving Average 13.46
Average True Range 1.04
RSI (14) 23.08
ADX 42.28
+DI 12.03
-DI 44.17
Chandelier Exit (Long, 3 ATRs) 15.45
Chandelier Exit (Short, 3 ATRs) 14.22
Upper Bollinger Bands 19.45
Lower Bollinger Band 10.82
Percent B (%b) 0.11
BandWidth 57.03
MACD Line -1.86
MACD Signal Line -1.63
MACD Histogram -0.2291
Fundamentals Value
Market Cap 781.95 Million
Num Shares 66.5 Million
EPS -3.71
Price-to-Earnings (P/E) Ratio -3.17
Price-to-Sales 300.67
Price-to-Book 4.29
PEG Ratio -0.64
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 12.47
Resistance 3 (R3) 12.50 12.28 12.35
Resistance 2 (R2) 12.28 12.09 12.27 12.31
Resistance 1 (R1) 12.01 11.98 11.90 11.99 12.27
Pivot Point 11.79 11.79 11.74 11.78 11.79
Support 1 (S1) 11.53 11.61 11.42 11.51 11.23
Support 2 (S2) 11.31 11.50 11.30 11.19
Support 3 (S3) 11.05 11.31 11.15
Support 4 (S4) 11.03